Get the Stockscreener App
4.54
0.66%
-0.03
After Hours:
4.56
0.02
+0.44%
Geron Corp stock is traded at $4.54, with a volume of 6.95M.
It is down -0.66% in the last 24 hours and down -4.42% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$4.57
Open:
$4.56
24h Volume:
6.95M
Relative Volume:
0.78
Market Cap:
$2.74B
Revenue:
$237.00K
Net Income/Loss:
$-184.13M
P/E Ratio:
-13.35
EPS:
-0.34
Net Cash Flow:
$-168.57M
1W Performance:
+6.07%
1M Performance:
-4.42%
6M Performance:
+37.58%
1Y Performance:
+114.15%
1-Day Range:
$4.49
$4.65
1-Week Range:
$4.30
$4.65
52-Week Range:
$1.64
$5.34
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
When Can We Expect A Profit From Geron Corporation (NASDAQ:GERN)? - Yahoo Finance
Geron's SWOT analysis: biotech firm's stock rides on Rytelo success - Investing.com
Renaissance Technologies LLC Takes $3.32 Million Position in Geron Co. (NASDAQ:GERN) - MarketBeat
7 Best NASDAQ Stocks Under $5 - Insider Monkey
Nasdaq Composite [TR] (XCMP) QuotePress Release - The Globe and Mail
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
U.S. Dollar Index (DXY) QuotePress Release - The Globe and Mail
Darwin Global Management Ltd. Acquires Shares of 23,915,480 Geron Co. (NASDAQ:GERN) - MarketBeat
Positive early demand trends for Geron’s Rytelo lead Goldman Sachs to reaffirm Buy rating - Investing.com
Affinity Asset Advisors LLC Sells 1,000,000 Shares of Geron Co. (NASDAQ:GERN) - MarketBeat
Farallon Capital Management LLC Grows Stock Holdings in Geron Co. (NASDAQ:GERN) - MarketBeat
Regeneron slides as Amgen wins Eylea biosimilar case; RBC still bullish - Investing.com
Groupon (GRPN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Geron: Derisked And Highly Attractive After Approval - Seeking Alpha
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
GERN’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Geron Corp. [GERN] moved down -0.63: Why It’s Important - The DBT News
Regeneron Pharmaceuticals’ (REGN) Overweight Rating Reiterated at Wells Fargo & Company - Defense World
Groupon Inc [GRPN] Investment Appeal on the Rise - Knox Daily
Geron (NASDAQ:GERN) Stock Price Down 4.5% - MarketBeat
337,752 Shares in GE Vernova Inc. (NYSE:GEV) Acquired by Gladstone Capital Management LLP - Defense World
Smart Money Is Betting Big In REGN Options - Benzinga
Head to Head Contrast: Mirage Energy (OTCMKTS:MRGE) vs. Gibson Energy (OTCMKTS:GBNXF) - Defense World
GoodRx Holdings Inc (GDRX)’s Market Momentum: Closing Strong at 6.91, Down -2.40 - The Dwinnex
Xponance Inc. Lowers Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Balance Sheet Breakdown: Rigetti Computing Inc (RGTI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
40 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Itau Unibanco Holding S.A. - Defense World
Examining Gorilla Technology Group Inc (GRRR) more closely is necessary - US Post News
Genmab A/S (NASDAQ:GMAB) Sets New 52-Week Low at $24.36 - Defense World
Morse Asset Management Inc Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Gabelli Funds LLC Takes $16.80 Million Position in GE Vernova Inc. (NYSE:GEV) - Defense World
Tri Locum Partners LP Purchases 46,577 Shares of argenx SE (NASDAQ:ARGX) - MarketBeat
GM Stock Is Falling After Downgrade by Former Bull - Barron's
Genel Energy Solidifies Leadership, Eyes Growth - TipRanks
Adversity is less terrifying than hope: Genesis Energy L.P. (GEL) - SETE News
Brighton Jones LLC Acquires Shares of 2,103 GE Vernova Inc. (NYSE:GEV) - Defense World
Brighton Jones LLC Cuts Position in General Motors (NYSE:GM) - Defense World
Groupon stock price rare pattern points to more downside - Invezz
Brokers Issue Forecasts for Greif, Inc.'s FY2024 Earnings (NYSE:GEF) - MarketBeat
Graco Inc. (NYSE:GGG) Shares Sold by Ameritas Investment Partners Inc. - Defense World
ProShare Advisors LLC Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Summit Trail Advisors LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Bridges Investment Management Inc. Makes New Investment in GE Vernova Inc. (NYSE:GEV) - Defense World
Skandinaviska Enskilda Banken AB publ Purchases Shares of 55,400 GE Vernova Inc. (NYSE:GEV) - Defense World
Benjamin Edwards Inc. Takes Position in Greif, Inc. (NYSE:GEF) - Defense World
Profund Advisors LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Massachusetts Financial Services Co. MA Increases Stake in Graco Inc. (NYSE:GGG) - Defense World
Benjamin F. Edwards & Company Inc. Purchases 612 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
DekaBank Deutsche Girozentrale Has $73,000 Holdings in Greif, Inc. (NYSE:GEF) - Defense World
Geron (GERN) to Report Q2 Earnings: What's in the Cards? - MSN
Legacy Financial Advisors Inc. Purchases 69 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Geron Corp Stock (GERN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer |
Jul 08 '24 |
Sale |
4.56 |
674,348 |
3,073,004 |
0 |
| Feller Faye | EVP, Chief Medical Officer |
Jun 10 '24 |
Option Exercise |
1.19 |
287,900 |
341,693 |
155,400 |
| Feller Faye | EVP, Chief Medical Officer |
Jun 10 '24 |
Sale |
4.63 |
287,900 |
1,334,129 |
0 |
| Kapur Anil | EVP, Corp Strategy & CCO |
Jun 10 '24 |
Option Exercise |
1.06 |
421,875 |
447,188 |
421,875 |
| Kapur Anil | EVP, Corp Strategy & CCO |
Jun 10 '24 |
Sale |
4.64 |
421,875 |
1,959,609 |
0 |
| SCARLETT JOHN A | Chairman, President and CEO |
Jun 04 '24 |
Option Exercise |
2.54 |
600,000 |
1,524,000 |
600,000 |
| SCARLETT JOHN A | Chairman, President and CEO |
Jun 04 '24 |
Sale |
4.00 |
600,000 |
2,400,000 |
600,000 |
| LAWLIS V BRYAN | Director |
May 15 '24 |
Option Exercise |
1.94 |
35,000 |
67,900 |
35,000 |
| LAWLIS V BRYAN | Director |
May 15 '24 |
Sale |
3.75 |
35,000 |
131,250 |
0 |
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):